Announcements Trials
Browse Landscape

Status

Completed 10Unknown 5Terminated 5Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 25Observational 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 4Invasive Early Breast Cancer 1

Interventions

Blood Specimen Collection 27Surveys and Questionnaires 24Magnetic Resonance Spectroscopy 10Observation 7Flow Cytometry 7Specimen Handling 6Amplified Fragment Length Polymorphism Analysis 6exemestane 5Radiotherapy 5Magnetic Resonance Imaging 5Immunoenzyme Techniques 5Biopsy 5Radiation 4Neoadjuvant Therapy 4Mental Status and Dementia Tests 4Genetic Testing 4Gene Expression Profiling 4Electroporation 4Data Collection 4Bevacizumab 4Trastuzumab 3Tomography, X-Ray Computed 3Tomography, Optical Coherence 3Therapeutics 3Surgical Procedures, Operative 3Sunitinib 3Sorafenib 3Registries 3Radiosurgery 3Psychiatric Rehabilitation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Observational × exemestane × Clear all
NCT01121549 2014-01-22

A Non-Interventional Study With AromasinĀ® As Adjuvant Treatment Of Invasive Early Breast Cancer

Pfizer

Terminated
378 enrolled 16 charts
Breast

Invasive Early Breast Cancer

NCT00776659 2013-11-19

An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin

Pfizer

Terminated
39 enrolled 7 charts
Breast

Breast Neoplasms

NCT01239745 2012-10-31

AromasinĀ® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer

Pfizer

Terminated
46 enrolled 9 charts
Breast

Breast Neoplasms

NCT01155063 2012-10-01

Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients

Pfizer

Terminated
89 enrolled 12 charts
Breast

Breast Neoplasms

NCT01305239 2012-04-10

ETAPE

Pfizer

Terminated
398 enrolled 10 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔